CRTI 06-0230 RD: Rapid Methods for Emergency Bioassay Chunsheng Li, Health Canada Gary Kramer, Health Canada Baki Sadi, Health Canada Diana Wilkinson,

CRTI 06-0230 RD: Rapid Methods for Emergency Bioassay

Chunsheng Li, Health CanadaGary Kramer, Health CanadaBaki Sadi, Health Canada

Diana Wilkinson, DRDC-Ottawa

Kui Yu, National Research CouncilYi Cui, National Research Council

Edward Lai, Carleton UniversityAmy Hrdina, Carleton UniversityNegar Bahraini, Carleton University

Project Introduction

• Project Background - Rapid bioassay is required to screen large population

- Po-210 and Sr-90 are two high risk but “difficult” radionuclides

• Design Objectives - Detection Limit: 10% of derived urine action level (Bq/L) based on

500 mSv committed effective dose equivalent from inhalation

- Urine throughput: 120 samples in the first 48 hours per system

- Feces throughput: 20 samples in the first 48 hours per system

Project Tasks

• Developing rapid methods for measuring Po-210 and Sr-90 in bioassay samples using “traditional approach”

- Based on currently available techniques

- Focusing on rapidness, sensitivity, accuracy, repeatability, and

field deployability etc

- Studying the metabolism of Po-210

• Exploring the application of new materials and new technology to radiation assessment

- Application of quantum dots in radiation measurement

- Application of magnetic nano-parrticles in sample preparation

Achievements To Date (I):Rapid Method for Sr-90 Bioassay

• RFigure 4: This spectrum shows yttrium-90 growth. From top to bottom: no yttrium, yttrium growth after 1 hour, 10 hours, and 96 hours respectively. Spectra from liquid scintillation counter Tri-Carb 3180 TR/SL.

Urine sample

Acidification & Transferring(5 minute)

Preconditioning & decolourization(10 minutes)

Complexation & pH adjustment(5 minutes)

Anion exchange separation(15 minutes)

Cocktail mixing &Liquid scintillation measurement

(15 minutes)

Baki, Sadi, Chunsheng Li, Sara Jodayree, Vera Kochermin, Edward Lai, Gary Kramer “A rapid bioassay method for the determination of Sr-90 in human urine samples”. Submitted to Health Physics, 2009

Chunsheng Li, Baki Sadi, Gerry Moodie, Joseph daka, Edward Lai, Gary Kramer “Field deployable Technique for Sr-90 emergency bioassay”. Sumitted to Radiation Protection Dosimetry, 2009

Sample 1 2 3 4 5

Urine (g) 19.9 19.0 19.1 19.7 19.2

90Sr Spiked (Bq) 46.7 44.8 45.1 46.4 45.4

Results from Triathler (Bq) 51.2 ± 0.3 49.4 ± 0.3 51.2 ± 0.3 49.7 ± 0.3 52.3 ± 0.3

Bri (%) 9.6 10.3 13.5 7.1 15.2

Br (%) 11.1

SB (%) 3.2

sisiiri CCCB /)(

n

i

rir N

BB

1

Where: Ci = the measured activity in each replicate sample i;

Csi = the spiked activity in each replicate sample i;

Bri = the relative bias of the measurement for replicate sample i;

Br = the relative bias of the measurement for the spiked level;

N = the number of replicates for the spiked level, in this work, N = 5.

11

2

N

BBS

N

irri

B

Achievements To Date (II):Application of QDs

Emission Wavelength (nm)400 12001000800600 1400

CdSCdS

CdSeCdSe

InP

HgS

CdTeCdTeZnSe

InAs

HgTe

• A

Robert Z Stodilka, Jeffrey JL Carson, Kui Yu, Md. Badruz Zaman, Chunsheng Li, and Diana Wilkinson “Optical Degradation of CdSe/ZnS Quantum Dots upon Gamma-Ray Irradiation”, J. Phys. Chem. C. 2009, 113, 2580-2585.

Yu, Kui; Cui, Yi; Zaman, Md. Badruz; Wilkins, Ruth; Li, Chunsheng; Wu, Xiaohua; Ouyang, Jianying; “Optical Response of CdSe Quantum Dots to Cs-137 γ Radiation” J. Nanoscience and Nanotechnology. 2009, Accepted.

Achievements To Date (III):Application of MNPs in Bioassay

Fe3+ + H2ODeprotonation

Fe(OH)x3-x

Fe2+ + H2ODeprotonation

Fe(OH)y2-y

Oxidation

DehydrationpH ~ 9

Fe3O4 Magnetite

Fe3O4 Fe3O4

OH

OH

OH

1. MAA2. (NH4)2S2O8

in H2O treated with SDS, 70oC 2 h

Fe

O

O

NIP-PMAA-coated magnetic particles

NIP-coated magnetic particles

Magnetic particles

Achievements To Date (IV):Metabolism of Po-210 in Rats

• Primary: volatile Po-210 species in excreta - Implicating the accuracy in radiation dose assessment - Implicating in radiation protection - Providing information for bioassay method development

• Secondary: IR imaging – change in thermal profile for invasive screening

• Secondary: excretion and bio-kinetics - Excretion via urine - Excretion via feces - Distributions in tissues/organs

Daily Volatile Excretion (All CPM Corrected to March 01, 2009)

0

5

10

15

20

25

30

35

40

45

50

Day 2 Day 3 Day 4 Day 5

Days

Act

ivit

y (C

PM

)

Low Dose

High Dose

THE

END